Withhigher selectivity than ibrutinib, acalabrutinib inhibits only BTK,TEC, BMX, and TXK.19,21 Zanubrutinib was approved in2019 to treat MCL in adults who previously received therapy.19,22 Zanubrutinib is similar to acalabrutinib with less activity on TECand ITK and also displays higher potency and selectivity for BTK thanibrutinib, with fewer “off-target” effects. The gene discussed is BTK; the disease is mantle cell lymphoma.